These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 18218783

  • 1. A mechanistic study to assess whether isoproterenol can reverse the negative chronotropic effect of fingolimod.
    Kovarik JM, Riviere GJ, Neddermann D, Maton S, Hunt TL, Schmouder RL.
    J Clin Pharmacol; 2008 Mar; 48(3):303-10. PubMed ID: 18218783
    [Abstract] [Full Text] [Related]

  • 2. Oral-intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects.
    Kovarik JM, Hartmann S, Bartlett M, Riviere GJ, Neddermann D, Wang Y, Port A, Schmouder RL.
    Biopharm Drug Dispos; 2007 Mar; 28(2):97-104. PubMed ID: 17230596
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics, pharmacodynamics, safety, and tolerability of single-dose fingolimod (FTY720) in adolescents with stable renal transplants.
    Ettenger R, Schmouder R, Kovarik JM, Bastien MC, Hoyer PF.
    Pediatr Transplant; 2011 Jun; 15(4):406-13. PubMed ID: 21585629
    [Abstract] [Full Text] [Related]

  • 4. The effect on heart rate of combining single-dose fingolimod with steady-state atenolol or diltiazem in healthy subjects.
    Kovarik JM, Lu M, Riviere GJ, Barbet I, Maton S, Goldwater DR, Schmouder RL.
    Eur J Clin Pharmacol; 2008 May; 64(5):457-63. PubMed ID: 18196225
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Absorption and disposition of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in healthy volunteers: a case of xenobiotic biotransformation following endogenous metabolic pathways.
    Zollinger M, Gschwind HP, Jin Y, Sayer C, Zécri F, Hartmann S.
    Drug Metab Dispos; 2011 Feb; 39(2):199-207. PubMed ID: 21045200
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Fingolimod (FTY720) in severe hepatic impairment: pharmacokinetics and relationship to markers of liver function.
    Kovarik JM, Schmouder RL, Hartmann S, Riviere GJ, Picard F, Voss B, Weiss M, Wagner F, Schmidt HH.
    J Clin Pharmacol; 2006 Feb; 46(2):149-56. PubMed ID: 16432266
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics of fingolimod (FTY720) and a combined oral contraceptive coadministered in healthy women: drug-drug interaction study results.
    David OJ, Ocwieja M, Meiser K, Emotte C, Jakab A, Wemer J, den Daas I, Schmouder R.
    Int J Clin Pharmacol Ther; 2012 Aug; 50(8):540-4. PubMed ID: 22735460
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Paradoxical effect of isoprenaline infusion.
    Brembilla-Perrot B, Muhanna I, Nippert M, Popovic B, Beurrier D, Houriez P, Terrier de la Chaise A, Claudon O, Louis P, Abdelaal A, State S, Andronache M, Suty-Selton C.
    Europace; 2005 Nov; 7(6):621-7. PubMed ID: 16216767
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects.
    Kovarik JM, Schmouder R, Barilla D, Wang Y, Kraus G.
    Br J Clin Pharmacol; 2004 May; 57(5):586-91. PubMed ID: 15089811
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.